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Abstract
Background: The effectiveness of female condoms for preventing HIV and sexually transmitted infections (STIs)
remains inconclusive. We examined the effects of female condoms on the acquisition of HIV and STIs.
Methods: We searched four databases, two trial registries, and reference lists of relevant publications in October
2018 and updated our search in February 2020. We screened search output, evaluated study eligibility, and
extracted data in duplicate; resolving differences through discussion. We calculated the effective sample size of
cluster randomised trials using an intra-cluster correlation coefficient of 0·03. Data from similar studies were
combined in a meta-analysis. We performed a non-inferiority analysis of new condoms relative to marketed ones
using a non-inferiority margin of 3%. We assessed the certainty of evidence using GRADE.
Results: We included fifteen studies of 6921 women. We found that polyurethane female condoms (FC1) plus male
condoms may be as effective as male condoms only in reducing HIV acquisition (1 trial, n = 149 women, RR 0.07,
95%CI 0.00–1.38; low-certainty evidence). However, the use of FC1 plus male condoms is superior to male condoms
alone in reducing the acquisition of gonorrhoea (2 trials, n = 790, RR 0.59, 95%CI 0.41–0.86; high-certainty evidence)
and chlamydia (2 trials, n = 790, RR 0.67, 95%CI 0.47–0.94; high-certainty evidence). Adverse events and failure rates
of FC1 were very low and decreased during follow up. Although the functionality of newer female condoms
(Woman’s, Cupid, Pheonurse, Velvet, and Reddy) may be non-inferior to FC2, there were no available studies
assessing their efficacy in preventing HIV and STIs.
Conclusion: The use of female plus male condoms is more effective than use of male condoms only in preventing
STIs and may be as effective as the male condom only in preventing HIV. There is a need for well conducted
studies assessing the effects of newer female condoms on HIV and STIs.
PROSPERO registration number: CRD42018090710
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Background
The disease burden resulting from unsafe sex, including
human immunodeficiency virus (HIV) infection and other
sexually transmitted infections (STIs), has profoundly
impacted the health of people in all parts of the world.
Globally, it is estimated that 77·3 million people have been
infected with HIV since the start of the HIV epidemic, with
approximately half of those infected dying from AIDS
related illnesses [1]. Although the incidence of HIV has
shown a decrease over the last seventeen years, there were
1·8 million newly infected people in 2017 [1]. In sub-
Saharan Africa, young women continue to lead in rates of
new HIV infection with three in four new infections being
amongst young girls aged 15–19 years [1, 2]. A vast major-
ity of new HIV and STI infections in Sub-Saharan Africa
occur through heterosexual transmission [3, 4]. In many
cases, STIs that go undiagnosed do not only lead to long-
term complications such as infertility and cervical cancer
but also enhance HIV susceptibility [5, 6]. Consistent con-
dom use remains the most effective barrier against the sex-
ual transmission of HIV. Male condoms have proven to be
80 to 90% effective [7, 8]. Unfortunately, the subordinate
status of women in many countries makes negotiating male
condom use with partners especially difficult [9, 10]. This
makes women particularly vulnerable to HIV infection and
other STIs like gonorrhoea, chlamydia, and syphilis. This
warrants the need for alternative methods and effective
female initiated methods for STI and HIV prevention.
The female condom is a female-initiated dual method of
contraception. In 1993, the polyurethane condom also
known as FC1 (Female Health Co., Chicago, IL, USA)
became the first female condom to be approved by the
United States Food and Drug Administration (USFDA) as
a contraceptive and a method of protection against STIs,
including HIV/AIDS [11]. It was replaced in 2009 by an
identical second generation female condom FC2, which is
made from synthetic latex and offers the advantage of hav-
ing a reduced cost of production [12, 13]. Currently, there
are four female condoms that have been prequalified by
the World Health Organization (WHO)/United Nations
Population Fund (UNFPA). These include the Cupid, FC2,
Velvet and the Woman’s condom [14]. There are several
others that are being developed and in process for UN
and FDA approval with the aim of reducing cost and in-
creasing acceptability [15, 16].
Despite variations in the designs of the different types of
female condoms that are available, they share common
components which include: an outer retention mechanism
that prevents invagination, a sheath that lines the vagina,
an internal retention mechanism that ensures the condom
stays within the vagina and an insertion feature that facili-
tates insertion of the condom [17]. Current prequalifica-
tion guidelines recommend that contraceptive efficacy
studies be conducted for novel female condom designs
that are not considered equivalent to an existing marketed
female condom with an established efficacy rate [18].
However, for new female condoms whose design and
specifications are sufficiently similar to those of a mar-
keted device with a known efficacy rate established from a
clinical effectiveness study, the clinical effectiveness of the
new female condom can be established on the basis of a
clinical study comparing the incidence of failures modes.
Also, the manufacturer may use a device that has been
evaluated directly against a device whose effectiveness is
known and has been shown to be non-inferior in the event
where there is no suitable marketed device available [18].
Why it is important to do this review
Although laboratory studies suggest that the female con-
dom may be as effective as the male condom in preventing
HIV and STIs [19], the evidence remains uncertain espe-
cially for the new generation female condoms. Several
reviews that have examined the effectiveness of female con-
doms in preventing STIs and HIV found a limited number
of randomized controlled trials [20, 21]. Furthermore, these
reviews are outdated and do not examine the functionality
of the more recent designs of female condoms that are in-
creasingly being manufactured to address the shortcomings
of the older ones. Our review is timely considering the
recent reclassification of the female condom from a class
III device to a class II device in September 2018 by the
USFDA [22]. This reclassification will simplify the regula-
tory process for the approval of newer female condoms,
ensuring that women have more contraceptive options
from which to choose. This move has the potential of
increasing availability, access, acceptability and uptake of
the female condom.
In this systematic review our primary aim was to
examine the evidence around the effectiveness of the
female condom on the prevention of HIV and other
STIs among women. We also assess the functionality of
new female condoms compared to the current widely
marketed FC2 female condom.
Methods
Criteria for considering studies for this review
The methods used to conduct this systematic review are
described in the published protocol [23]. We included ran-
domised controlled trials (both individually and cluster
randomised) in women engaged in heterosexual activity in
any setting, with no clinical or laboratory-confirmed signs
of STIs. Included trials compared the female condom with
placebo, or other barrier methods for HIV and/or STI pre-
vention. Our outcomes of interest were the Incidence of
HIV, and the Incidence of STIs (including but not limited
to chlamydia, gonorrhoea, syphilis, herpes simplex virus,
trichomoniasis, Lymphogranuloma venereum, HPV, bac-
terial vaginosis) and adverse events. We had aimed to
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assess the effectiveness of the newer female condoms in
preventing HIV and other STIs. However, we did not find
any published or unpublished studies that assessed this
outcome. Available studies mostly assessed the functional-
ity of new types of female condoms, hence we synthesized
the evidence around the functionality of these condoms by
assessing the condom clinical failure rates as defined by
Beksinska et al. 2007 [24]. We included trials in which the
FC1 or FC2 were compared top each other, or compared
to any other marketed female condoms.
Search methods for identification of studies
Using a comprehensive search strategy, we searched
PubMed, Cochrane Central Register of Controlled Trials
(CENTRAL) and EMBASE on the 9 October 2018 with
no restrictions. Our search strategy was updated in Feb-
ruary 2020. We used the terms ‘female condom’, ‘HIV’,
and ‘sexually transmitted diseases’. Details of our search
terms can be found in the published protocol. We also
searched the reference lists of previous reviews [20, 21],
as well as articles included in this review for relevant
studies we may have missed through the electronic
search of peer-reviewed literature. We searched the
WHO International Clinical Trials Registry Platform
(ICTRP) and ClinicalTrials.gov for ongoing trials. All
identified records were deduplicated using Mendeley ref-
erence management software.
Study selection
Two authors (RKB and EJK, RKB and CSW or AW and
PM) independently screened the titles and abstracts ob-
tained from the electronic searches, as well as the full text
of all potentially eligible studies for relevance using a stan-
dardised eligibility form with predefined inclusion criteria.
Disagreements between the authors who assessed study
eligibility were resolved by discussion and consensus. Fol-
lowing the eligibility assessment, we classified all studies
that met our inclusion criteria as included. Studies that
met the design, intervention and participant inclusion cri-
teria but with relevant outcomes not yet available were
classified as ongoing (if the study was not yet completed)
or awaiting assessment (if the study was completed but
the data not yet published and we could not get any rele-
vant outcome data from trial investigators). We excluded
studies that did not meet our inclusion criteria and stated
the reasons for exclusion.
Data extraction and management
Two authors independently extracted data using a stan-
dardised data extraction form and performed risk of bias
assessment. Extracted information included the study
details, participant details, intervention details and out-
come details. We assessed the risk of bias for RCTs
using the Cochrane risk of bias tool for randomized
controlled trials as described in the Cochrane Handbook
for Systematic Reviews of Interventions [25]. For cross-
over and cluster RCTs, we assessed for risk of bias spe-
cific to these study designs as described in the Cochrane
Handbook for Systematic Reviews of Interventions [25].
Disagreements between the authors who extracted data
and assessed risk of bias were resolved by discussion and
consensus. We planned to asses for publication bias
using a funnel plot, but this was not done due to the in-
sufficient number of studies reporting the various out-
come measures. Data were entered into Review Manager
5.3 (RevMan 5.3) software and checked for accuracy.
Dichotomous data were presented and compared using
risk ratios with 95% confidence intervals. We assessed het-
erogeneity between trial results by visually inspecting the
forest plots for overlapping of confidence intervals,
followed by the chi-squared test of homogeneity (with
significance defined at an alpha level of 10%). We then
used the I2 test to quantify the degree of heterogeneity.
We analysed the data using RevMan 5.3 and Excel statis-
tical software. We conducted meta-analysis when included
studies were similar in terms of participants, interventions,
and outcomes. We pooled the study results using the
Mantel-Haenszel method and the fixed model effects.
When there was substantial heterogeneity, we used the
random-effects model. When the I2 was greater than 50%,
we considered it to be substantial heterogeneity and ex-
plored the cause of heterogeneity using subgroup analyses.
When the studies were not similar enoiugh to be meta-
analysed, we narratively synthesised the evidence.
For cluster randomised trials, we reduced each trial to
its effective sample size by dividing its original sample by
the design effect; where the design effect equals 1 + (M –
1) * ICC (Higgins 2011). M is the average cluster size
and ICC is the intracluster correlation coefficient. We
used an ICC of 0·03 which was reported by one of the
included studies. Finally, we assessed the quality of the
evidence using the Grading of Recommendations, As-
sessment, Development and Evaluations (GRADE) ap-
proach, as outlined in the GRADE handbook [26].
In order to assess non inferiority of new female con-
doms to widely marketed ones, we used the WHO/
UNFPA guidelines for female condom generic specifica-
tion, prequalification and procurement [18]. As stated in
this guideline, included studies were required to have a
minimum of 200 women, with at least 5 uses of each
condom type. Non inferiority was demonstrated by cal-
culating the difference of total clinical failure rates be-
tween the new female condom and the marketed one.
The upper bound of the one-sided 95% confidence inter-
val of this difference was expected to be less than 3% for
non-inferiority [18]. We conducted both per protocol
and intention to treat analysis for all relevant trials using
random effects model [27].
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Results
Figure 1 summarises our search and selection process.
We identified 2325 records during our initial search in
2018. An updated search in 2020 identified 121 new re-
cords. We screened 1948 titles and abstracts after re-
moving duplicates. Thirty-one records met our inclusion
criteria. Following full text assessment, independent re-
view and discussion of the thirty-one full-text articles,
we included fifteen studies published in eighteen articles.
We searched clinicaltrials.gov and the WHO ICTRP
and found 4 relevant trial records. Two trials had no
comparator arms, the results from one trial had been
published and included amongst the included trials, and
the results of one completed crossover trial posted in
2010 in which the Program for Appropriate Technology
in Health (PATH) Woman’s Condom and the FC2 Fe-
male Condom were compared could not be found [28].
Included studies
Study designs
The study designs include: Two cluster randomised trials
[29, 30], ten crossover trials including three non-
inferiority trials [31–39], and three randomized con-
trolled trials [40, 41]. See Table 1.
Participants
The number of participants in each study ranged from
55 to 1929 women over 15 years old. The fifteen studies
included a total of 6921 women. Accounting for the de-
sign effect in the two cluster-randomised trials with
2477 participants (using an intra-cluster correlation co-
efficient of 0·03 reported by one of them) their com-
bined effective sample size becomes 790 participants.
The included studies were mostly conducted in
women in low-income and middle-income countries:
South Africa (n = 5), China (n = 1), China and South Af-
rica (n = 1), Thailand (n = 1), Kenya (n = 1), Zimbabwe
(n = 1) and Brazil (n = 1). In one study (an abstract), the
authors did not mention the country where the study
was conducted [46]. Three trials were conducted in high
income setting, all in the USA. The women in these
studies included both those considered to have a high
risk of HIV/STI transmission such as female sex
workers, and women in monogamous relationships
judged as having a low risk. See Table 1.
Interventions
Four trials compared the polyurethane female condom
(FC1) plus male condom to the male condom only. In
Fig. 1 Study flow diagram
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three trials, participants in the intervention group were
given a combination of FC1 and male condoms [29, 30,
41], In the fourth trial, the women in the intervention
group were given FC1 and had access to male condoms
[40]. Two crossover studies compared the female con-
dom to the male condom. At different sequences,
women were randomly assigned to use FC1 or male con-
doms [31, 32]. The focus of these two studies was mainly
to assess mechanical problems and semen exposure
while using female condoms.
In eight crossover trials, the functionality of new fe-
male condoms was compared against widely marketed
ones; one trial compared FC2 to FC1 [33], the Woman’s
condom was compared to the FC1 in one trial and in
seven trials the FC2 was compared to new female con-
doms. More information is provided in Table 1.
Outcomes
The main outcomes reported in studies that compared
the female plus male condom to the male condom only
were incidence of STI, mechanical problems and adverse
events. Only one study reported on the effect of female
plus male condoms on HIV transmission [41]. In two
studies, semen exposure was measured using prostate
specific antigen [31, 47].
Amongst studies that compared the functionality of
new female condoms against widely marketed ones, fe-
male condom failure modes were the main outcomes re-
ported. The failure modes reported were breakage,
slippage, misdirection, invagination, total clinical failure
and total failure rates.
Excluded studies
We excluded eleven articles for the following reasons:
non randomized trial (n = 5) [47–51], before and after
study (n = 1) [52], cross sectional study (n = 1) [53], co-
hort study (n = 3) [54–56], both arms received female
condoms and it was not the main intervention (n = 3)
[42–44]. See Fig. 1.
Risk of bias in included studies
We assessed the included studies for selection bias. One
study assigned participants to intervention arm based on
the week of initial visit and this was scored as high risk
for random sequence generation and unclear risk for al-
location concealment [40]. Three studies failed to pro-
vide sufficient information and were scored as having
unclear risk of bias for both random sequence gener-
ation and concealment [31, 36]. Three studies reported
adequately on the methods of random sequence gener-
ation but failed to report on allocation concealment and
were scored as having unclear risk of bias for allocation
concealment [29, 30, 37]. The rest of the studies ad-
equately reported random sequence generation and
allocation concealment and were judged to have low risk
of bias for both domains.
With regards to blinding, it was generally difficult to
blind the participants and to some extent the research
personnel due to the nature of the female condom. All
studies had unclear risk of bias for blinding of partici-
pants and personnel. All except one study had unclear
risk of bias for blinding of outcome assessors [40].
There was high risk of attrition bias in three studies;
Macaluso 2007 reported attrition rates of 42% [32] In
the study by French 2003, only 50·2% of the female/male
condom arm and 51·1% of the male condom only arm
completed at least one visit [40]. Fontanet 1998 reported
that forty-four women had no follow-up at all, 11 (4·3%)
from the male condom group, and 33 (11·7%) from the
male/female condom group. Almost half of the study
participants were lost to follow-up after 3 months [29].
Six studies were judged as having low attrition rates [30,
34, 35, 38, 39, 45] and the rest were rated as unclear.
Three studies were rated as having low risk of reporting
bias, with the rest providing insufficient information to
enable judgement, hence judged to have unclear risk of
bias.
Other potential sources of bias
In four studies, the authors reported support from com-
panies that manufacture female condoms including;
Chartex international [29, 41], the Female Health Com-
pany [40], and Cupid Ltd. [35] The support included free
condom supplies in one study and funding in three stud-
ies and both condom supplies and funding in one study.
Details about how potential conflicts of interest were
handled are not described. We rated these studies as
having unclear risk of bias due to lack of enough infor-
mation to make a definitive judgement. Two studies did
not provide information regarding funding and were also
considered to have unclear risk of bias. We had planned
to assess for publication bias using a funnel plot. This
was not done due to the small number of studies.
In cross-over trials, participants randomly receive a se-
quence of different treatments. These trials are prone to
carryover bias which occurs when participants are
switched from one intervention to another without an
adequate washout period in-between. Due to the nature
of the intervention in this review, we judged the poten-
tial for carryover bias to be low. We have summarised
the risk of bias in included studies in Table 2.
Effects of female condoms on HIV and other STIs
Comparison of the female (plus male) condom to the male
condom only
All studies included in this comparison used the polyur-
ethane female condom also known as the FC1.
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Incidence of HIV
One study including 149 participants compared the
effect of the female plus male condom to the male
condom only on the incidence of HIV infection [41].
This was a randomized controlled trial conducted in
Zimbabwe amongst female sex workers. During the
study, no woman in the female plus male condom group
became HIV infected, while three women became HIV
positive in the male condom only group. However this
difference was not statistically significant (RR 0·07, 95%
CI 0·00 to 1·38).
Incidence of STIs
Four studies that compared the female plus male con-
dom to the male condom, reported on this outcome [29,
30, 40, 41]. Three of these studies compared the female
plus male condom to the male condom only [29, 30, 41]
and one compared the female condom alone to the male
condom though the authors report that over one third
of the women in the female condom group had access to
and used the male condom [40]. Three of these trials, in-
cluding 2232 women reported this outcome in a manner
that was similar enough to be combined.
As seen in Fig. 2, the use of the female plus male con-
dom significantly reduces the risk of any STI when com-
pared to male condom only (RR 0·74, 95% CI 0·62 to
0·89; I2 = 23%). When the data were disaggregated, the
use of female plus male condoms compared to male
condoms only significantly reduced the risk of gonor-
rhoea (2 trials, n = 790 participants, RR 0·59, 95%CI
0·41 to 0·86) and chlamydia (2 trials with 790 partici-
pants, RR 0·67, 95%CI 0·47 to 0·94). The pooled effect
estimate was not significant for trichomoniasis (2 tri-
als with 790 participants, RR 1·01, 95%CI 0·63 to
1·60) and genital ulcer disease (1 trial with 475 partic-
ipants, RR 4·72 95% CI 0·23 to 97·87).
Adverse events and condom failure
Three studies reported adverse events. Ray 2001 found
that 14% of the participants reported problems, irritation
or discomfort with the use of the female condom [41].
Fontanet 1998 reported that the female condom was
well tolerated, with no reports of genital lesions that
could be attributed to the use of the female condom
[29]. Galvao 2005 evaluated the frequency of self-
reported acceptability problems. These included non-
menstrual vaginal bleeding during intercourse, pain or
discomfort felt by either the male or the female partner
and noise made by the condom during use. The fre-
quency of acceptability problems was higher in the fe-
male condom group [31].
Table 2 Summary of risk of bias in included studies
Low risk, High risk, Unclear risk.
Fig. 2 Forest plots of comparison male + female condom versus male condom on the risk of STI
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None of the six included studies that compared the
male to the female condom reported on the total clinical
failure rates or total condom failure rates. However, four
studies reported on at least one of the four categories of
failure: breakage, invagination, misdirection and slippage.
Due to heterogeneity in the reporting of condom failure
modes between the included studies, the findings could
not be meta-analysed. Two studies reported on breakage;
Fontanet 1998 and colleagues reported that male con-
doms tore more often than female condoms (2·8% com-
pared to 0·5%) [29]. Similarly Macaluso 2007 found that
when compared to the male condom, the female con-
dom had lesser reported cases of breakage (0·3% vs
1·3%) [32]. With regards to slippage, both Fontanet 1998
and Macaluso 2007 found that slippage rates during use
were higher for the female condom than the male con-
dom: 5·7% versus 1·3% and 10·6% vs 2·1 for complete
slippage, 2·6% for partial slippage ≥1 in. and 1·7% for
partial slippage ≤1 in. respectively [29, 32]. The authors
further highlight that the proportion of female condoms
slipping in or out decreased during follow up visits. Two
studies found that the rates of invagination for the fe-
male condom were generally low. Ray 2001 reported in-
vagination in 3·4% of cases and Macaluso 2007 reported
a rate of 3% [32, 41]. Three studies reported on misdir-
ection, which was generally low. Fontanet 1998 and Ray
2001 each reported misdirection in 3.0% of cases
amongst those who used the female condom and Maca-
luso 2007 reported a rate of 5·6% [29, 32, 41]. Galvao
2005 compared the rates of mechanical problems be-
tween the male and female condom groups [31]. Male
condom mechanical problems were grouped together
and included breakage during intercourse, total or par-
tial slippage either during intercourse or during with-
drawal and semen leakage on the woman’s body. Female
condom mechanical problems were equally grouped to-
gether and included; breakage during intercourse, slip-
page, misdirection, invagination, semen leakage onto the
woman’s body, condom clung to penis, moving with it
during intercourse and problems encountered by the
participants with the inner ring during intercourse. In
this study, female condoms had significantly higher rates
of self-reported mechanical problems than male con-
doms (20% vs 12%). For each condom type, women who
received in-clinic educational instructions on the female
and male condoms reported lesser mechanical problems
compared with those who had to read the condom pack-
age inserts (FC: 6% vs 14% and MC: 4% vs 8%).
Functionality studies
Comparison of the FC2 to the FC1
One crossover trial conducted in Durban South Africa
and including 276 women, compared the functionality of
FC2 to FC1 [33]. Each study participant was required to
use ten of each condom type with their partners within
a 2 to 3 month study period. Approximately one quarter
of the study participants were lost to follow up during
the study. Functionality measures assessed were break-
age (clinical, nonclinical and total), incorrect penetra-
tion, outer ring displacement (partial, complete and
total), and slippage (partial and complete). Though twice
as many women reported incorrect penetration with
FC1 than FC2, there was no statistically significant dif-
ference in the total clinical failure rates between both
condoms (RR 0·81, 95% CI 0·61 to 1·08). The number of
participants reporting discomfort and adverse events in-
cluding; discomfort during and after insertion, pain after
insertion before sex, pressure causing urge for mictur-
ition, discomfort during sex, device uncomfortable to
use and bleeding were similar in both groups. There was
a non-significant excess number of cases of burning/rash
or itching in the FC2 group (RR 11·00, 95% CI 0·61 to
198·83). The effect on HIV incidence is not reported.
One case of STI, presenting as a white discharge and
confirmed using syndromic management was reported
in the FC1 group (RR 0·33 95% CI 0·01 to 8·18) [33].
Though the authors did not state that this was a non-
inferiority trial, it was powered enough to establish non
inferiority. The difference of the total clinical failure
rates of the FC2 compared to FC1 met the criteria for
non-inferiority when we used both per protocol and
Intention to treat analysis (RD -0·01, 95% CI − 0·02 to
0·00).
Comparison of new female condoms to the FC2 and the
FC1
One study including 75 women compared the FC1 to
the Woman’s condom [39] and seven studies including
1994 women compared the FC2 condom to other types
of female condoms [34–38, 45, 46]. The Woman’s con-
dom resulted, in non-significantly lower rates of total
clinical failure (RR 0·72 95% CI 0·51 to 1·02) when com-
pared to the FC1. However, there was a significantly
lower rates of total condom failure (RR 0·74 95% CI 0·59
to 0·93) and adverse events (RR 0·28 95% CI 0·17 to
0·46). In addition to the standardised definition of failure
modes [24], the author’s definition of clinical failure
rates in this trial includes other measures such as the
partial turning inside out of the female condom as their
measures of female condom performance were adapted
from those of the male condom [39, 57]. This study was
not powered enough to establish non-inferiority.
When we considered the seven studies that compared
the new female condoms to the FC2, there was no sig-
nificant difference in the total clinical failure rates when
the cupid/cupid 2 condoms (2 trials, n = 900, RR 1·22
95% CI 0·98 to 1·52) [34, 35], Velvet condom (1 trial,
n = 300, RR 0·90 95% CI 0·63 to 1·29) [35], Woman’s
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condom/Woman’s condom 2 (3 trials, n = 1058, RR 0.84
95% CI 0·68 to 1·04) [34, 38, 45], Reddy female condom
(2 trials, n = 770, RR 0·85 95% CI 0·65 to 1·11) [34, 38],
and Pheonurse (1 trial, n = 291, RR 1·00 95% CI 0·92 to
1·08) [37] were compared to the FC2. One conference
abstract for a trial comparing the Wondaleaf condom to
the FC2 reported total clinical failure rates of 5·3% and
7·5% respectively [36]. Another abstract describing a
study in which the functionality of the China female
condom (FCc) was compared to the FC2 reported total
clinical failure rates of 0.9 and 1.1% for the FCc and the
FC2 respectively [46]. The difference in total clinical fail-
ure rates was deemed non-significant. The full text of
this article was unavailable. We examine the risk differ-
ence and found that the functionality of the cupid,
cupid, Velvet condom, Woman’s condom, Reddy and
phoenurse may be non-inferior to the FC2 based on the
clinical failure rates, without any differences observed in
per protocol and intention to treat analysis (see Fig. 3).
The trial comparing the Wondaleaf condom to FC2 was
not powered enough to demonstrate non-inferiority.
Four studies compared the total condom failure rate
between the FC2 and other types of female condoms.
There was no significant difference in total female con-
dom failure rates when the Cupid/Cupid2 condoms (2
trials, n = 900, RR 1·16 95% CI 0·96 to 1·40) [34, 35], Vel-
vet condom (1 trial, n = 300, RR 0·88 95% CI 0·66 to
1·18) [35], Woman’s condom (2 trials, n = 878, RR 0.84
95% CI 0·49 to 1·46) [34, 45], Reddy female condom (1
trial, n = 600, RR 0·87 95% CI 0·65 to 1·15) [34] were
compared to the FC2. None of the studies that com-
pared the new female condoms to the FC2 assessed their
direct effects on the incidence of HIV infection or STIs.
Discussion
Summary of the main results
In this review, we aimed to assess the effects of the fe-
male condom in preventing HIV and other STIs among
women. Available evidence suggest that there may be no
difference in the incidence of HIV infection when
women used the polyurethane female condom plus the
male condom compared to those who used the male
condom only. However, female plus male condom re-
duces the risk of gonorrhoea and chlamydia and prob-
ably reduces the risk of trichomonas and other STIs
when compared to the male condom only. Adverse
events associated with use of the female condom were
generally few and not life threatening. Condom breakage
was more frequently reported amongst users of the male
condom and slippage amongst users of the female con-
dom. The rates of invagination and misdirection of the
female condom were low ranging from 3 to 3.4% and 3–
5.6% respectively.
We note however that there were no eligible studies
assessing the effectiveness of the new female condoms in
preventing HIV and STIs. Available studies assessed the
functionality of these new condoms against existing ones
for the purpose of prequalification.
One study comparing the functionality of the FC2 to
the FC1 found it to be non-inferior. The cupid, cupid 2,
Fig. 3 Non-inferiority of new female condoms compared to the FC2 showed using estimates of the risk differences in the total clinical
failure rates
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Velvet, Woman’s, Reddy and Pheonurse, condoms were
non-inferior to the FC2 based on their total clinical fail-
ure rates. Functionality studies which are often required
for prequalification showed that FC2 was equivalent to
FC1 based on non-clinical and functionality data, hence
a full contraceptive efficacy study on FC2 was not neces-
sary. However, this may not be the case for many of the
new types of female condoms which, warranting the
need for contraceptive efficacy studies.
Data from self-reports show that the usage of the fe-
male condom was generally poor in the intervention
arms. French et al. in a sub study found that male con-
doms accounted for one third of the condom protected
sex acts in the female condom group [40]. Feldblum
et al. also highlight that though female condom distribu-
tion increased in the female plus male condom group,
39 and 58% of the women reported never using the fe-
male condom at 6 months and 12month follow up visits
[29]. Fontanet 1998 instructed women to use the female
condom as a backup when clients refused to use male
condoms and the use of the female condom remained
limited, accounting for only 12% of all sexual acts [29].
Ray found that though the proportion of women in the
female + male condom group who consistently used the
male condom increased, only 3–9% of women reported
consistently using the female condom with clients dur-
ing the study [41]. This further highlights the import-
ance of high-quality studies assessing the acceptability of
female condoms in the targeted populations.
Certainty of the evidence
The strength of this review lies in our adherence to the
standardised guidelines on the conduct and reporting of
systematic reviews [25]. We used the GRADE approach
to assess the certainty of the evidence as shown in the
summary of findings table 3 [26]. We judged the quality
of evidence for FC1 plus male condoms compared to
male condoms only as low and moderate in reducing the
risk of HIV and STIs respectively. The certainty of the
evidence was downgraded for very severe imprecision in
the case of HIV and high risk of bias in the case of STIs.
We rated the certainty of the evidence for the effect of
FC1 plus male condom in preventing gonorrhoea and
chlamydia as high. The effects of the FC1 plus male con-
dom in preventing genital ulcer disease and trichomon-
iasis were rated as moderate. In both instance, we
downgraded for severe imprecision.
Table 3 Summary of findings table Female condom + male condom compared to Male condom only for prevention of HIV an STIs
Patient or population: prevention of HIV an STIs Intervention: Female condom + male condom Comparison: Male condom only
Outcome № of
participants
(studies)
Relative effect
(95% CI)
Anticipated absolute effects (95% CI) Certainty
Difference
HIV infection
№ of participants: 149
(1 RCT)
RR 0.07
(0.00 to 1.38)
6.0% 0.4%
(0 to 8.3)
5.6% fewer
(6 fewer to 2.3 more)
⨁⨁◯◯
LOW a
Any STI
№ of participants: 2232
(3 RCTs)
RR 0.74
(0.62 to 0.89)
24.9% 18.4%
(15.5 to 22.2)
6.5% fewer
(9.5 fewer to 2.7 fewer)
⨁⨁⨁◯
MODERATE b
Gonorrhoea
№ of participants: 790
(2 RCTs)
RR 0.59
(0.41 to 0.86)
15.2% 9.0%
(6.2 to 13.1)
6.2% fewer
(9 fewer to 2.1 fewer)
⨁⨁⨁⨁
HIGH
Chlamydia
№ of participants: 790
(2 RCTs)
RR 0.67
(0.47 to 0.94)
16.0% 10.7%
(7.5 to 15)
5.3% fewer
(8.5 fewer to 1 fewer)
⨁⨁⨁⨁
HIGH
Trichomonas
№ of participants: 790
(2 RCTs)
RR 1.01
(0.63 to 1.60)
8.0% 8.1%
(5 to 12.8)
0.1% more
(3 fewer to 4.8 more)
⨁⨁⨁◯
MODERATE a
Genital ulcer disease
№ of participants: 457
(1 RCT)
RR 4.72 (0.23 to 97.87) 0.0% 0.0%
(0 to 0)
0.0% fewer
(0 fewer to 0 fewer)
⨁⨁⨁◯
MODERATE a
CI Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility
that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
Explanations
aIncludes only one study with small sample size and wide confidence intervals
bHigh risk of selection bias due to lack of proper randomization in one of the trials
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The certainty of the evidence from studies comparing
the Woman’s condom to the FC1, and the Wondaleaf
condom to the FC2 was judged to be of low mostly due
to severe imprecision resulting from the small number
of study participants. The certainty of the non-inferiority
analysis comparing the functionality of the FC2 to the
FC1 and the cupid, cupid 2, Velvet, Woman’s, Reddy,
Pheonurse, condoms to the FC2 was rated as moderate,
downgrading for imprecision.
Agreements and disagreements with other studies or
reviews
Several reviews have attempted to answer our review
question [12, 20, 21]. Minnis and colleagues in 2004
reviewed the evidence around the effectiveness of the fe-
male condom in preventing STIs from three random-
ized trial and one prospective cohort study. They
reported that results from these studies provide evi-
dence that female condom confer as much protection
from STIs as male condom [20]. A review by Gallo
et al. in 2013 examined the evidence from random-
ized and non-randomised studies. They argue that al-
though female condoms (or a combination of female
plus male condoms) may provide similar degrees of
protection against pregnancy and STIs as do latex
male condoms alone, they called for more compara-
tive research to demonstrate this [12]. Vijayakumar
and colleagues in 2006 reviewed 137 articles and ab-
stracts (mainly observational studies) on various as-
pects of female condoms. Based on five randomized
trials on effectiveness, the authors concluded that
there is limited but convincing evidence that the fe-
male condom is effective in increasing protected sex
(five studies) and decreasing STI incidence (two stud-
ies) among women [21]. Our findings are consistent
with theirs. However, our systematic review goes a
step further by using GRADE to ascertain the cer-
tainty of the evidence. In addition to evaluating the
effects of widely marketed condoms, we reviewed the
functionality of new female condoms (including the
Woman’s, Cupid, Pheonurse, Velvet and Reddy,con-
doms) based on evidence from more recent trials, and
found them to be non-inferior when compared to
widely marketed ones.
Differences between protocol and review
There are several differences between the review proto-
col and the final review [23]. We had planned to include
both randomised and non-randomised trials in this re-
view in order to assess the effectiveness, safety and ac-
ceptability of the female condom. However, in this
review we included only randomised trials used to assess
the effectiveness and safety of the female condom. This
was due to the large number of studies identified which
explored issues around acceptability. This outcome will
be addressed in a separate review. Also, we had planned
to include trials that compared the female condom to no
treatment or other barrier methods for HIV prevention,
for example, male condom, microbicides, diaphragm, va-
ginal sponges and cervical caps. In this review, we also
compared the functionality of different types of new fe-
male condoms to existing ones using a non-inferiority
analysis. Although the non-inferiority analysis and mar-
gins were nor prespecified in our protocol, the risk of
bias in this non inferiority analysis is low, considering
that the non-inferiority margin is already set by the
WHO/UNFPA guidelines [18]. Finally, we had planned
to assess the possibility of publication bias by construct-
ing a funnel plot but this was not done due to the small
number of studies that reported our outcomes of
interest.
Potential biases in the review process
This systematic review was conducted using methods
described in the Cochrane Handbook for systematic re-
views of interventions [25] and reported in accordance
with the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) items [58]. We are
not aware of any biases in the review process. We how-
ever highlight that a major limitation of included studies
is that condom usage is ascertained based on self-reports
by study participants. An objective marker of semen ex-
posure would reduce the risk of recall bias [59].
Conclusion
The use of female and male condoms (when women are
given the option to make a choice of one or both at each
sexual act) is more effective than use of male condoms
only in preventing chlamydia and gonorrhoea and prob-
ably more effective in preventing trichomoniasis and
other STIs. There may be no difference between male
and female condoms in preventing HIV, however, the
certainty of the evidence is low and warrants further re-
search. This research is critical considering that the fe-
male condom used in the studies that have provided the
evidence base for the effectiveness of the female condom
in preventing HIV and STI used the FC1 which is no
longer in the market. Such studies should be adequately
powered and should equally assess acceptability and ad-
verse events. The advent of new female condoms that
may be non-inferior to previous and currently marketed
ones provide women with more protection options. Al-
though studies suggest that they may be non-inferior to
older female condoms, it is equally important for high
quality trials to be conducted that assess the effective-
ness of these new condoms in the prevention of HIV
and STIs.
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